👋 Hey, let’s get into it. Pharma pricing just got a lot more aggressive.

The Trump administration is floating tariffs of up to 100% on branded drugs that do not align with U.S. pricing expectations. The strategy is simple: force global pharma companies to either lower domestic prices or face steep import penalties. That puts immediate pressure on companies that rely heavily on U.S. revenue while manufacturing or pricing internationally.

Some players moved early. Eli Lilly, Pfizer, and Novo Nordisk have already struck pricing agreements, effectively insulating themselves for now. Others are scrambling to evaluate their options, weighing price cuts against supply chain shifts or even domestic manufacturing investments.

This is not just about pricing anymore. It is about control over where drugs are made, how they are priced, and who ultimately absorbs the cost. If this policy sticks, it could reshape global pharma strategy in a way we have not seen before.

💰 Neurocrine Drops $2.9B for a Rare Disease Shortcut
Neurocrine is buying Soleno Therapeutics for $2.9 billion in cash, grabbing Vykat XR in the process, the first approved treatment for hyperphagia in Prader-Willi syndrome. The deal comes with a 34% premium and gives Neurocrine immediate revenue in a space where it previously had early-stage bets. Vykat XR is already generating sales and could cross $2 billion globally over time, making this less of a science gamble and more of a strategic fast-track into metabolic disease.

📉 Pharma’s Pipeline Growth Finally Hits a Wall
For the first time in decades, the global drug pipeline shrank. After years of nonstop expansion, the total number of drugs in development dipped nearly 4% to just under 23,000. Some of that is data cleanup, but the bigger story is slower new project starts and tighter R&D budgets. Oncology still dominates, while neuroscience quietly gains ground. The industry is no longer in pure expansion mode. It is getting selective.

🤖 Anthropic Pays $400M for a 10-Person Biotech
AI giant and future ruler of humanity Anthropic just spent around $400 million to acquire Coefficient Bio, a startup that is barely eight months old and has fewer than 10 employees. The team comes from Genentech’s computational biology ranks, and the bet is clear: AI-native drug discovery is worth paying up for early. Big Pharma is already using Anthropic’s tools, and this move pushes it deeper into life sciences. Expensive, yes, but waiting might cost more.

🇬🇧 U.K. Locks In Zero Pharma Tariffs With a Catch
The U.K. just secured 0% tariffs on pharma exports to the U.S., becoming the first country to pull it off. The trade-off is higher domestic costs, with the NHS expected to pay about 25% more for new drugs alongside looser cost-effectiveness thresholds. The deal is designed to attract pharma investment, but early reactions have been cautious.

💰 Pfizer Wins $2.2B Court Fight
Poland and Romania were ordered to pay damages after canceling COVID vaccine contracts, marking a major legal win for Pfizer in Europe.

🏛️ HHS Faces 12.5% Budget Cut
The White House proposal would slash $15.8 billion from HHS while pushing a broader restructuring of federal health agencies and programs.

🫁 AstraZeneca Combo Shows Promise
Imfinzi plus Imjudo improved progression-free survival in liver cancer patients, reinforcing AstraZeneca’s push into combination immunotherapy strategies across oncology.

🪓 Gilead Axes HIV Trial
Gilead scrapped a midstage HIV study after ongoing FDA clinical holds created uncertainty around timelines and regulatory approval pathways.

💉 Lyme Vaccine Still Alive
Valneva said its missed Phase 3 endpoint may still be “negotiable” with regulators, keeping hopes alive for its Lyme disease vaccine program.

💸 Syneron Bio Raises $150M
The peptide drug platform continues attracting capital despite tighter biotech funding conditions, signaling sustained investor interest in next-generation therapeutic approaches.

The GLP-1 battle has moved from injections to pills, and now it’s a real fight.

We covered this in the April 2 issue, but GLP-1s are “so hot right now,” we’re going deeper and breaking down Novo vs Lilly’s pill showdown. Now let’s get into it.

Eli Lilly and Novo Nordisk are officially going head to head in oral obesity drugs, but this is not a clean knockout situation. It is a tradeoff game. Novo’s oral Wegovy leads on efficacy, showing around 16.6% weight loss in late-stage trials. Lilly’s Foundayo comes in lower, around 11 to 12%. If this were purely about results, Novo would have the edge.

But it’s not.

Lilly is leaning into convenience and scalability. Foundayo can be taken without strict timing and diet requirements. Novo’s pill needs to be taken on an empty stomach with a waiting period before eating. That added friction may seem small, but in real-world use, it can impact adherence in a meaningful way.

Then there is manufacturing. Lilly’s pill is a small molecule, which is generally easier and cheaper to produce at scale. Novo’s is a peptide, which adds complexity and cost. Over time, that difference could influence pricing flexibility, margins, and global access.

On pricing, both companies are entering at similar levels around $149 per month for starter doses, with higher doses increasing from there. Neither is aggressively undercutting the other yet, suggesting both see long-term value in holding the line.

Investors appear to favor Lilly for now. Novo’s stock has struggled while Lilly continues to build momentum across obesity and beyond. Still, Novo has an early lead in prescriptions and stronger efficacy data, which matters for certain patient populations.

This is not about one drug winning. It is about who builds the more durable ecosystem around obesity treatment. Time will tell.

That is how often scientists’ jokes actually land, based on an analysis of more than 500 conference presentations. Most attempts get polite chuckles or silence. Turns out curing disease is easier than landing a punchline.

Here’s what biotech Redditors are talking about:

🤔 Promotion by Ultimatum?
One biotech professional was told the only way to get promoted was to threaten to leave. The community response was blunt: in this job market, that’s a dangerous game. A few years ago, maybe it works. Today? Companies might just call your bluff. The smarter move is to quietly job hunt first and keep leverage real, not theoretical.

🌴 San Diego Dream… or Reality Check?
A biotech contractor debated leaving Boston for San Diego, only to get hit with a cold dose of reality. The consensus: Boston still dominates for biotech jobs, while San Diego is brutally slow right now. Great weather doesn’t pay the bills, especially when homes are $1M and roles are scarce. The advice: stay put, stack experience, and wait for the market to rebound.

🧠 Takeda Walks Away From Dementia Bet
After eight years of development, Takeda returned program rights to Denali, officially exiting its long-running partnership focused on neurodegenerative disease therapies.

🤖 AI Designs Addiction Drug
Researchers developed a new compound using AI that reduced opioid cravings in rats without major side effects, highlighting early promise in addiction treatment.

💉 COVID Trial Hits Enrollment Wall
Pfizer and BioNTech halted a large U.S. COVID study after enrollment slowed significantly, reflecting reduced urgency and shifting priorities in post-pandemic research.

☢️ Radiotherapy Gains Momentum
Targeted radiation therapies are emerging as a major oncology platform, with increasing investment and clinical success driving renewed interest across biotech and pharma.

🧠 Epia Neuro Turns Brain Signals Into Movement
Epia Neuro is building a brain computer interface to help stroke patients regain function by translating neural signals into digital commands. The minimally invasive implant sits in the skull, learns user intent, and connects to assistive devices powered by AI. With fast implantation and long-term usability, the company is betting that restoring movement starts with decoding intention.

🌍 April 7, 1948 — The World Health Organization Is Born
The WHO was established with a mission to achieve the highest possible level of health worldwide. It has since led efforts like smallpox eradication, polio reduction, and global vaccine coordination. From pandemics to policy, it remains one of the most influential forces in global health.

Some scientists spend eight months perfecting a joke for a presentation with only a 9% chance it lands.

Meanwhile, Coefficient Bio started a company and exited for $400M in the same amount of time.

Use your time wisely.

That’s all for today. See you Thursday for the next issue. 👋

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead